Mersana Therapeutics Announces Initiation of Expansion Study of XMT-1536 in Patients with Platinum-Resistant Ovarian Cancer and Non-Small Cell Lung CancerGlobeNewsWire • 08/20/19
Mersana Therapeutics, Inc. (MRSN) CEO Anna Protopapas on Q2 2019 Results - Earnings Call TranscriptSeeking Alpha • 08/10/19
Mersana Therapeutics, Inc. (MRSN) CEO Anna Protopapas on Q1 2019 Results - Earnings Call TranscriptSeeking Alpha • 05/12/19
JPMorgan Downgrades Mersana, Says Data Readouts Unlikely To Reverse Street SentimentBenzinga • 03/11/19